135 related articles for article (PubMed ID: 9167912)
1. Strategies for immunoprophylaxis and immunotherapy of papillomaviruses.
Frazer I
Clin Dermatol; 1997; 15(2):285-97. PubMed ID: 9167912
[No Abstract] [Full Text] [Related]
2. Papillomavirus vaccines.
Duggan-Keen MF; Brown MD; Stacey SN; Stern PL
Front Biosci; 1998 Dec; 3():D1192-208. PubMed ID: 9835649
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus vaccines.
Stanley MA
Curr Opin Mol Ther; 2002 Feb; 4(1):15-22. PubMed ID: 11883690
[TBL] [Abstract][Full Text] [Related]
4. Immunology of the human papilloma virus in relation to cancer.
Wu TC
Curr Opin Immunol; 1994 Oct; 6(5):746-54. PubMed ID: 7826530
[TBL] [Abstract][Full Text] [Related]
5. [Prophylactic and therapeutic vaccine therapy in papillomavirus infections].
Vinatier D; Cosson M; Dufour P
Gynecol Obstet Fertil; 2000 May; 28(5):370-84. PubMed ID: 10893881
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus vaccine development.
Fife KH
Australas J Dermatol; 1998 Nov; 39 Suppl 1():S8-10. PubMed ID: 9842094
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, properties and applications of papillomavirus-like particles.
Sapp M; Volpers C; Streeck RE
Intervirology; 1996; 39(1-2):49-53. PubMed ID: 8957669
[TBL] [Abstract][Full Text] [Related]
8. Humoral immune response to human papillomavirus infection.
Carter JJ; Galloway DA
Clin Dermatol; 1997; 15(2):249-59. PubMed ID: 9167909
[No Abstract] [Full Text] [Related]
9. Vaccine regimen for prevention of sexually transmitted infections with human papillomavirus type 16.
Kowalczyk DW; Wlazlo AP; Shane S; Ertl HC
Vaccine; 2001 May; 19(25-26):3583-90. PubMed ID: 11348726
[TBL] [Abstract][Full Text] [Related]
10. Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies.
Kawana K; Kawana Y; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
Vaccine; 2001 Jan; 19(11-12):1496-502. PubMed ID: 11163673
[TBL] [Abstract][Full Text] [Related]
11. Immune response to human papillomaviruses and the prospects for human papillomavirus-specific immunisation.
Tindle RW; Frazer IH
Curr Top Microbiol Immunol; 1994; 186():217-53. PubMed ID: 8205843
[No Abstract] [Full Text] [Related]
12. The end for genital human papillomavirus infections?
Stanley M
Lancet Oncol; 2005 May; 6(5):256-7. PubMed ID: 15863371
[No Abstract] [Full Text] [Related]
13. Vaccination against papillomavirus in cattle.
Campo MS
Clin Dermatol; 1997; 15(2):275-83. PubMed ID: 9167911
[No Abstract] [Full Text] [Related]
14. Papillomavirus-like particle vaccines.
Schiller JT; Lowy DR
J Natl Cancer Inst Monogr; 2001; (28):50-4. PubMed ID: 11158207
[TBL] [Abstract][Full Text] [Related]
15. Induction of neutralizing antibodies to papillomaviruses by anti-idiotypic antibodies.
Christensen ND; Reed CA; Cladel NM
Virology; 1995 Jul; 210(2):292-301. PubMed ID: 7542415
[TBL] [Abstract][Full Text] [Related]
16. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes.
Roden RB; Yutzy WH; Fallon R; Inglis S; Lowy DR; Schiller JT
Virology; 2000 May; 270(2):254-7. PubMed ID: 10792983
[TBL] [Abstract][Full Text] [Related]
17. [Perspectives for the development of vaccines and immunotherapy against cervico-uterine cancer].
Guzmán-Rojas L; Alcocer-González JM; Madrid-Marina V
Salud Publica Mex; 1998; 40(1):38-46. PubMed ID: 9567657
[TBL] [Abstract][Full Text] [Related]
18. A message from Preventive Medicine and your physician.
Prev Med; 1999 Jun; 28(6):543-4. PubMed ID: 10404551
[No Abstract] [Full Text] [Related]
19. HPV vaccine moves into late stage trials.
Connett H
Nat Med; 2001 Apr; 7(4):388. PubMed ID: 11283639
[No Abstract] [Full Text] [Related]
20. Human papillomavirus antigens and T-cell recognition.
Luxton J; Shepherd P
Curr Opin Infect Dis; 2001 Apr; 14(2):139-43. PubMed ID: 11979123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
